Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Topical AT-004 1% in Participants With Acne Vulgaris.

NCT07774364 is registered in ClinicalTrials.gov with Arctic Therapeutics as lead sponsor.

NCT NCT07774364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07774364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Topical AT-004 1% in Participants With Acne Vulgaris.
Lead sponsor
Arctic Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
February 2, 2026
Completion date
July 29, 2026
Enrollment
63 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acne vulgaris on the face